ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2477

Descriptive Patterns of Switches and Swaps in Patients with Rheumatoid Arthritis Initially Treated with Anti-TNF Agents in First Intention between 2000 and 2006, and 2007 and 2015 – Experience from a Real-World Database RHUMADATA®

Denis Choquette1, Louis Bessette2, L Coupal3 and Kirsten Garces4, 1University of Montreal Hospital Research Centre (CRCHUM), Notre Dame Hospital Montreal, Montreal, QC, Canada, 2Groupe de Recherche en Rhumatologie et Maladies Osseuses, Quebec, Quebec, QC, Canada, 3Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 4Amgen Canada Inc., Mississauga, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Anti-TNF therapy and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Between 2000 and 2006, the only other treatment option for patients with rheumatoid arthritis (RA) first exposed to an anti-TNF agent was another anti-TNF agent. After 2006, agents with a different mode of action became available.  The patterns of switches (anti-TNF to anti-TNF) and swaps (anti-TNF to another mode of action) have not been presented in detail. The real-world experience gathered since 2000 gives us a unique opportunity to examine change in prescribing patterns.

Methods: The data of biologic naïve RA patients starting a first anti-TNF [adalimumab (ADA), certolizumab (CER), etanercept (ETA), golimumab (GOL), infliximab (INF) or inflectra] between January 1, 2000 and December 31,2006 (first era), and January 1, 2007 and December 2015 (second era) was extracted. Patients were followed until they stopped, changed their medication or were lost to follow-up. Switches or swaps could happen at any time. We analyzed the number of patients that stopped, switched or swapped in each treatment era and the time from initial treatment to second treatment or the cessation of treatment. Statistical analysis was performed using SAS version 9.4.

Results:   The choice of a second biologic agent among patients having been prescribed their initial between Jan 1, 2000, and Dec 31, 2006, and Jan 1, 2007, and Dec 31, 2015, are presented Table 1. In the first era, switches accounted for 45.9% of cases, with most switching to ETN (42%), followed by ADA (30.6%), INF (19.7%), CER (3.8%), GOL (3.2%) and inflectra (0.6%). In the second era, switches accounted for 31.5% of cases, with most switching to ETN (31.7%), ADA (23.2%), CER (19.5%), GOL (15.9%), INF (7.3%) and inflectra (2.4%).  Swaps accounted for 26.0% of cases in the first era. These swaps occurred towards abatacept (ABA), rituximab (RTX), tocilizumab (TOCI) and anakinra in 48.3%, 34.8%, 16.9% and 9.0% of cases. In the second era, the proportion of swaps increased to 38.8% and occurred towards ABA, RTX, TOCI and tofacitinib (TOFA) accounting for 42.6%, 26.7%, 24.8% and 5.9% of cases.

Conclusion:   When switching occurs, most patients switched to a second anti-TNF in the first and second era.  ETN was the anti-TNF more often selected for the in both eras. In the second era, there was an increased tendency to prescribe agents with a different mode of action after the first anti-TNF agent. This may be due to the availability of biologics with a different mode of action.

Table 1.


Disclosure: D. Choquette, Abbive, Amgen, BMS, Celgene,Eli Lilly, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Janssen, Sandoz, 8,Abbive, Amgen, BMS, Celgene,Eli Lilly, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Janssen, Sandoz, 5,Abbive, Amgen, BMS, Celgene,Eli Lilly, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Janssen, Sandoz, 2; L. Bessette, Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, 8,Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, 5,Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, Sanofi, 2; L. Coupal, None; K. Garces, Amgen, 1,Amgen, 3.

To cite this abstract in AMA style:

Choquette D, Bessette L, Coupal L, Garces K. Descriptive Patterns of Switches and Swaps in Patients with Rheumatoid Arthritis Initially Treated with Anti-TNF Agents in First Intention between 2000 and 2006, and 2007 and 2015 – Experience from a Real-World Database RHUMADATA® [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/descriptive-patterns-of-switches-and-swaps-in-patients-with-rheumatoid-arthritis-initially-treated-with-anti-tnf-agents-in-first-intention-between-2000-and-2006-and-2007-and-2015-experience-from-a/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/descriptive-patterns-of-switches-and-swaps-in-patients-with-rheumatoid-arthritis-initially-treated-with-anti-tnf-agents-in-first-intention-between-2000-and-2006-and-2007-and-2015-experience-from-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology